Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intermittent selection pressure with zidovudine plus zalcitabine treatmentreduces the emergence in vivo of zidovudine resistance HIV mutations
Autore:
Izopet, J; Sailler, L; Sandres, K; Pasquier, C; Bonnet, E; Aquilina, C; Puel, J; Massip, P; Marchou, B;
Indirizzi:
CHU Toulouse, Hop Purpan, Virol Lab, F-31059 Toulouse, France CHU Toulouse Toulouse France F-31059 Virol Lab, F-31059 Toulouse, France Hop Purpan, Serv Malad Infect & Trop, Toulouse, France Hop Purpan Toulouse France , Serv Malad Infect & Trop, Toulouse, France Hop La Grave, Serv Dermatol, Toulouse, France Hop La Grave Toulouse France La Grave, Serv Dermatol, Toulouse, France
Titolo Testata:
JOURNAL OF MEDICAL VIROLOGY
fascicolo: 2, volume: 57, anno: 1999,
pagine: 163 - 168
SICI:
0146-6615(199902)57:2<163:ISPWZP>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-LEVEL RESISTANCE; ACTIVE ANTIRETROVIRAL THERAPY; TYPE-1 REVERSE-TRANSCRIPTASE; POL GENE-MUTATIONS; COMBINATION THERAPY; DRUG-RESISTANCE; IN-VIVO; CUBIC MILLIMETER; VIRAL LOAD;
Keywords:
zidovudine; zalcitabine; resistance mutations; intermittent treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Izopet, J CHU Toulouse, Hop Purpan, Virol Lab, F-31059 Toulouse, France CHU Toulouse Toulouse France F-31059 F-31059 Toulouse, France
Citazione:
J. Izopet et al., "Intermittent selection pressure with zidovudine plus zalcitabine treatmentreduces the emergence in vivo of zidovudine resistance HIV mutations", J MED VIROL, 57(2), 1999, pp. 163-168

Abstract

The development of mutations conferring drug resistance was investigated in 49 antiretroviral-naive asymptomatic HIV-1 subjects with CD4(+) cell counts of 250-500/mm(3) given intermittent (6-week courses, 6 weeks apart) or continuous treatment with zidovudine (AZT) plus zalcitabine (ddC) over 54 weeks. The concentration of human immunodeficiency virus type 1 RNA in the plasma and the CD4 cell counts were measured every 6 weeks. The rate of decrease of HIV-1 RNA concentration in plasma after a 6-week course of AZT + ddCwas similar for each treatment cycle (approximately 1-log reduction). The plasma HIV-1 RNA concentration returned to its initial level at each treatment interruption. The mean CD4 cell counts after 54 weeks in the two treatment groups were similar. Genotype analysis by sequencing the reverse transcriptase coding region from plasma viral RNA on treatment showed a lower frequency of AZT resistance mutations after 54 weeks in patients given intermittent treatment (18%) than in those treated continuously (79%, P < 0.001). No mutations conferring ddC resistance or multidideoxy-nucleoside resistance were observed in either group. These findings may have clinical implications for long-term treatment strategies. (C) 1999 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 04:49:25